Sunshine Biopharma, Inc. (SBFMW) has a negative trailing P/E of -0.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 7.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -135.17%, forward earnings yield 14.39%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.1 | 0.00 | -2.03 | 0.00 | - |
| 2017 | -19,965.5 | 233.46 | -36,222.83 | 0.00 | - |
| 2018 | -226.1 | -0.46 | -8,743.71 | 1,090.09 | - |
| 2019 | -1.0 | 0.00 | -2.16 | 75.21 | - |
| 2020 | -0.5 | 0.01 | -1.42 | 19.04 | - |
| 2021 | -0.6 | 0.00 | 36.06 | 33.42 | - |
| 2022 | -0.4 | 0.01 | 0.45 | 2.24 | - |
| 2023 | -1.5 | 0.02 | 0.31 | 0.27 | - |
| 2024 | -0.4 | 0.00 | 0.09 | 0.06 | - |
| 2025 | -0.9 | 0.01 | 0.22 | 0.14 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-164.63 | $0.00 | $-3.5M | - |
| 2017 | $-23.84 | $0.00 | $-1.04M | - |
| 2018 | $-142.00 | $447.2K | $-2.16M | -482.1% |
| 2019 | $-18,866.90 | $21.12K | $-1.66M | -7860.9% |
| 2020 | $-3,214.89 | $71.41K | $-2.78M | -3898.7% |
| 2021 | $-9,520.00 | $228.43K | $-12.44M | -5444.2% |
| 2022 | $-3,523.64 | $4.35M | $-26.74M | -615.4% |
| 2023 | $-351.36 | $24.09M | $-4.51M | -18.7% |
| 2024 | $-7.32 | $34.87M | $-5.13M | -14.7% |
| 2025 | $-1.44 | $36.31M | $-5.98M | -16.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.32 | $-0.32 – $-0.32 | $50M | $50M – $50M | 1 |
| 2027 | $0.02 | $0.02 – $0.02 | $45M | $45M – $45M | 1 |
